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Abstract
Objective
To report a series of patients with cerebral arteriopathy associated with heterozygous variants in
the casitas B-lineage lymphoma (CBL) gene and examine the functional role of the identified
mutant Cbl protein. We hypothesized that mutated Cbl fails to act as a negative regulator of the
RAS-mitogen-activated protein kinases (MAPK) signaling pathway, resulting in enhanced
vascular fibroblast proliferation and migration and enhanced angiogenesis and collateral vessel
formation.
Methods
We performed whole-exome sequencing in 11 separate families referred to Great Ormond
Street Hospital, London, with suspected genetic cause for clinical presentation with severe
progressive cerebral arteriopathy.
Results
We identified heterozygous variants in the CBL gene in 5 affected cases from 3 families. We
show that impaired CBL-mediated degradation of cell surface tyrosine kinase receptors and
dysregulated intracellular signaling through the RAS-MAPK pathway contribute to the path-
ogenesis of the observed arteriopathy. MutatedCBL failed to control the angiogenic signal relay
of vascular endothelial growth factor receptor 2, leading to prolonged tyrosine kinase signaling,
thus driving angiogenesis and collateral vessel formation. Mutant Cbl promoted myofibroblast
migration and proliferation contributing to vascular occlusive disease; these effects were ab-
rogated following treatment with a RAF-RAS-MAPK pathway inhibitor.
Conclusions
We provide a possible mechanism for the arteriopathy associated with heterozygous CBL
variants. Identification of the key role for the RAS-MAPK pathway in CBL-mediated cerebral
arteriopathy could facilitate identification of novel or repurposed druggable targets for treating
these patients and may also provide therapeutic clues for other cerebral arteriopathies.
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The casitas B-lineage lymphoma (CBL) gene encodes a mem-
ber of the Cbl family of proteins that function as a RING finger
E3 ubiquitin ligase.1 This Cbl protein has an N-terminal
phosphotyrosine binding domain that interacts with tyrosine-
phosphorylated substrates to target them for proteasome
degradation.2 Through this process, the Cbl protein acts as
a negative regulator of signal transduction pathways, such as the
RAS-mitogen-activated protein kinases (MAPK) signaling
pathway.3 Previous reports have identified that missense
mutations in CBL cause a disorder characterized by impaired
growth, cryptorchidism, predisposition to juvenile myelomo-
nocytic leukemia, and systemic arteriopathy in some cases.4–7
Isolated cases of cerebrovascular disease have also been
reported in association with heterozygous de novomutations in
CBL.4,6 The exact mechanism of the observed arteriopathy
remains unclear, however. Here, we identified heterozygous
CBL variants in 5 individuals with cerebral arteriopathy from 3
separate families (figure 1, A–C) and for the first time exam-
ined the functional role of mutant Cbl protein in this context.
We hypothesized that mutated Cbl fails to act as a negative
regulator of the RAS-MAPK signaling pathway, resulting in
enhanced vascular fibroblast proliferation, migration, and en-
hanced angiogenesis and collateral vessel formation.
Methods
Standard protocol approvals, registrations,
and patient consents
This study was approved by the Bloomsbury ethics committee
(ethics number 08H071382). We obtained written informed
consent from all the family members and controls who par-
ticipated, and additionally for children, written assent where
appropriate.
Patients
We screened 11 families where the index case was presenting
with suspected genetic cerebral arteriopathy due to disease
onset from early in life, other affected family members, or
presence of dysmorphic features. All cases were referred for
specialist opinion to the vasculitis and neurovascular service at
Great Ormond Street Hospital, London, between October
2016 and January 2019. Ischemic strokes were diagnosed on
the basis of the presence of cerebral infarct on confirmatory
cerebral imaging or diagnosis of a TIA.8 Cerebral/cervical
arteriopathy was defined as focal or segmental arterial stenosis
or occlusion, with regular or irregular abnormalities of the
arterial wall and categorized according to current consensus
definitions.8,9 Diagnosis of moyamoya arteriopathy was based
on cerebrovascular imaging demonstrating stenosis or oc-
clusion of the terminal portion of the internal carotid artery,
the formation of an abnormal vascular network in the vicinity
of the arterial occlusion, and review of the patient’s history
and images for exclusion of other causes of arterial stenosis.8,9
In vitro studies were performed in patient- and age-sex–
matched healthy control–derived peripheral blood mono-
nuclear cells (PBMCs), cultured dermal fibroblast cells,
transformed smooth muscle cell (SMC)-like cells, human
brain vascular adventitial fibroblasts (HBVAFs; ScienCell,
Carlsbad, CA), and human umbilical vein endothelial cells
(HUVECs; PromoCell, Heidelberg, Germany).10,11
Genetic mapping and sequencing
Trios were genotyped using the Illumina cytoSNP12 chip. A
total of 200 ng of DNA was isothermally amplified overnight
and then enzymatically fragmented. The fragmented DNA was
incubated on a BeadChip overnight. These were imaged using
the Illumina iScan Read. Whole-exome sequencing was com-
pleted using the Illumina and sequenced on the Illumina
HiSeq2000. The raw sequence data were aligned to the human
reference genome using the Burrows-Wheeler Aligner align-
ment algorithm. Variant calling was with the Genome Analysis
ToolKit. Variant annotation was with wANNOVAR. Anno-
tated data from whole-exome sequencing were screened in the
first instance for rare novel or rare nonsynonymous variants
(<0.01) in the 1000 Genomes Project and Genome Aggrega-
tion Database. For every rare variant, we assessed pathoge-
nicity, novelty, and predicted functional impact using SIFT,
PolyPhen-2, MutationTaster, and Alamut Batch version 2.11.
The identified variants were individually assessed and classified
into pathogenicity groups (Class 1: clearly not pathogenic;
Class 2: unlikely to be pathogenic; Class 3: unknown signifi-
cance; Class 4: likely to be pathogenic; and Class 5: clearly
pathogenic), according to the Association of Clinical Genetics
Science Practice Guidelines 2013 guidelines.12 Variant confir-
mation and familial segregation were ascertained by PCR, and
sequencing was completed with the AB3730 using the BigDye
v3.1 kit (Applied Biosystems, Foster City, CA).
Cbl-induced ubiquitination assay
PBMCs were isolated from heparinized blood using Ficoll
separation. Cbl ubiquitination activity was measured using the
Ubiquitylation Assay Kit (Abcam, Cambridge, UK). Protein
was extracted from PBMCs using M-PERmammalian protein
extraction reagent (Thermo Fisher Scientific, Waltham, MA),
supplemented with protease inhibitor cocktail. A total of
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150 mg of whole cell lysate was incubated with rabbit anti-Cbl
(Santa Cruz) and with Protein A agarose beads (Santa Cruz,
Dallas, TX). Washed Cbl immunoprecipitates were used for
ubiquitination assay, as per manufacturer instructions.
Fibroblast culture and myofibroblast trans-
differentiation
Human dermal fibroblast cells (HDFCs) were explanted from
patients heterozygous for CBL mutations and from controls
without any identifiable vascular disease. HDFCs and com-
mercially available HBVAFs were cultured in basal medium
(Ham F10 Nutrient Mix). For trans-differentiation, HDFCs
were evenly seeded on matrigel precoated plates. After
overnight incubation, cells were treated with 2% heat-
inactivated horse serum and 5 ng/mL transforming growth
factor β1 to induce fibroblast trans-differentiation into SMC-
like cells. The cells were harvested on day 14 for RNA iso-
lation. qPCR analysis was performed to analyze mRNA
Figure 1 Loss of CBL-mediated ubiquitination activity in mutant CBL cells results in reduced Cbl-regulated cell surface
receptor degradation and enhanced cellular tyrosine kinase signaling
(A–C) Pedigrees for all 3 studied families show the affected and unaffected family members; segregation of CBL variants is also shownwhere genetic sequencing
was available. (D and E) Axial T2 and apparent diffusion coefficient map from the diffusion-weighted imaging for A-II-3 showed an acute right largely cortically
based right middle cerebral artery (MCA) territory infarct (long blue arrow). Mature deep and cortical left anterior cerebral artery (ACA)/MCA watershed infarcts
indicate previous left hemispheric injury (short red arrows). (F–H) Catheter digital subtraction angiography for A-II-3 showed a right internal carotid artery (ICA)
stenosiswith some filling of a narrow rightMCAbranchandoccluded right ACA (red arrow) andmultiplemoyamoya, ethmoidal, and ophthalmic collateral vessels
(blue arrow). (G) The left ICAwas occluded just beyond the left PCA (red arrow) and ACA branch can be seen to fill via collaterals. The collateral pattern is similar to
the right with additional pial collaterals from the left PCA (blue arrow). (H) The posterior circulation vessels were normal and fill the cerebral hemispheres via
collateral pial vessels (arrow). (I) Peripheral bloodmononuclear cells (PBMCs) frompatientswith heterozygousmutations inCBL (B-III-1 andB-III-2) were lysed and
immunoblotted with an anti-CBL antibody, followed by a ubiquitination assay using a known Cbl substrate, epidermal growth factor (EGFR), and compared with
control cells. The blot shown here indicates impaired Cbl-mediated EGFR ubiquitination in PBMCs with mutated Cbl. (J) PBMCs from patients with heterozygous
CBLmutationswere stimulatedwith 20ng/mL EGF for the indicatedperiods of time and stained to explore changes in EGFR expression. Relative EGFRexpression
was increased for patient-derived cells at all time points compared with EGFR expression for healthy control cells, p = 0.03. (K) Similarly, there was increased
phosphorylation ofMAPK inpatient PBMCs comparedwith control cells at all timepoints, p = 0.008. Datawere expressed as fold change relative tomeanbaseline
expression for control andplottedasmeanof triplicate samples ± SEM. p<0.05 calculatedbyanalysis of varianceandunpaired t testswere considered significant.
CBL = casitas B-lineage lymphoma; MAPK = mitogen-activated protein kinase.
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expression of an SMC marker gene (ACTA2). The migratory
potential of these cells was assessed with a wound healing
scratch assay. Fibroblasts were cultured until confluency in
6-well culture plates, as described above. A scratch was made
in the confluent monolayer with a plastic disposable pipette
tip (200 μL). Cultures were washed twice with PBS to remove
all detached cells. The wound area was photographed at t =
0 and t = 24 hours with a phase contrast microscope. The
migrated area was determined by subtracting the wound area
at these time point and cells migrating in the area counted.
Matrigel assays: HUVEC capillary networks
HUVECs were cultured in EGM-2 medium supplemented
with 2% fetal calf serum, hydrocortisone, fibroblast growth
factor 2, vascular endothelial growth factor (VEGF), R3-
insulin-like growth factor 1, epidermal growth factor, heparin,
ascorbic acid, gentamycin, and amphotericin B, as supplied by
the manufacturer (PromoCell) at 37°C in 5% CO2 in a hu-
midified incubator. HUVECs at 80% confluency (passages
2–5) were used for experiments. Matrigel assays were used to
examine the ability of HUVECs to form endothelial capillary
networks.8 Growth factor–reduced Matrigel matrix (Becton
Dickinson Labware, Oxford, UK) was thawed and placed in
96-well plates at 37°C for 30 minutes to solidify. HUVECs (1
× 104 cells/well) were seeded onto polymerized Matrigel and
incubated in EGM-2 medium at 37°C for 16 hours. The
cultures were photographed with an Olympus TH4-200 mi-
croscope. Capillary-like tube networks were observed, and the
branch point number of 5 independent fields each well was
counted.10
Flow cytometric analysis of EGFR,
phosphorylatedMAPK, PLC-γ1, Ki67 expression
in PBMCs, HUVECs and HDFCs and
SMC myofibroblasts
Before stimulation, HUVECs, HDFCs, HBVAFs, and SMC
myofibroblasts were washed with sterile PBS and put in qui-
escent (basal) media for 24 hours. PBMCs were left in normal
media overnight after being extracted or thawed. HUVECs
were stimulated with 20 ng/mL recombinant human VEGF
165 protein (R&D Systems,Minneapolis, MN); PBMCs were
stimulated with 20 ng/mL epidermal growth factor (EGF)
recombinant human protein (Thermo Fisher Scientific), and
transformed HDFCs were stimulated with 20 ng/mL platelet-
derived growth factor (PDGF) A/B (PeproTech, Rocky Hill,
NJ). To detect the expression of epidermal growth factor
receptor (EGFR), PBMCs were fixed and permeabilized using
BD Cytofix/CytopermTM after stimulation with EGF. Cells
were stained with a monoclonal antibody against EGFR
(Santa Cruz), followed by a secondary antibody, a rabbit anti-
mouse Alexa 488 (Life Technologies, Carlsbad, CA). To
detect phosphorylatedMAPK expression in PBMCs, HDFCs,
HBVAFs, and SMCmyofibroblasts and phosphorylated PLC-
γ1 expression on HUVECs, following the stimulations, cells
were fixed in prewarmed BD Cytofix buffer for 10 minutes at
37°C. Cells were then washed and permeabilized with BD
Phosflow Perm Buffer III for 30 minutes at 40°C. After cells
were incubated with the primary antibody for p-MAPK or p-
PLC-γ1 (Cell Signaling Technology, Danvers, MA) for 60
minutes on ice, cells were washed and stained with the sec-
ondary antibody, goat anti-rabbit Alexa 488 (Life Technolo-
gies) for further 45 minutes on ice. To assess Ki67 expression,
resting or stimulated (with growth factor) cells were stained
with FITC-conjugated anti-Ki67 (1:50 dilution; Miltenyi
Biotec, Bergisch Gladbach, Germany) antibody. The expres-
sion of EGFR, p-MAPK, and phospholipase C-γ1 (PLC-γ1)
and Ki67 was detected by flow cytometry analysis using an
FACScalibur flow cytometer (BD Biosciences, Franklin
Lakes, NJ).
RAF-RAS-MAPK inhibitor effect on fibroblast
proliferation and migration
Fibroblasts were pretreated with 5 μM of sorafenib, a protein
kinase inhibitor that targets the RAF-RAS-MAPK pathway,
for 30 minutes before stimulation with 20 ng/mL PDGF, and
their migratory and proliferative capacity was then assessed.
siRNA CBL transfection in fibroblasts
and HUVECs
siRNA knockdown was performed in primary fibroblasts
(HDFCs and HBVAFs) or HUVECs via transient trans-
fection using with 100 nM of siRNA targeting CBL (SC-
29242; Santa Cruz) or a negative control. siRNAs (SC-
37007; Santa Cruz) were transfected via complexation
with Lipofectamine RNAiMAX (13778-075; Life Tech-
nologies) according to the manufacturer’s instructions. At
48 hours post-transfection, knockdown efficiency was
evaluated by quantitative real-time PCR. The QuantiTect
CBL primers were used (QT00070301; Qiagen, Hilden,
Germany).
Histopathology
Immunohistochemistry was performed using Phospho-
p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E)
XP Rabbit Monoclonal Primary Antibody (Catalogue No.
4370s) (Cell Signaling Technology, Beverly, MA), diluted
at 1:50 on a Leica Bond-Max autostainer (Leica Biosystems,
Melbourne, Australia) and the Leica Bond Polymer Refine
Detection kit (Reference No. DS9800). Antigen retrieval
was by heat-induced epitope retrieval, Leica Epitope Re-
trieval protocol 1 for 20 minutes, pH 6. The tissue sections
were counterstained with hematoxylin.
Data availability
The authors confirm that the data supporting the findings of
this study are available within the article.
Statistical analyses
Results were independently reviewed by 2 scientists (A.K. and
Y.H.). Results were expressed as mean and SEM or median
and range. All statistics (repeated-measures analysis of vari-
ance and unpaired Student t tests) were produced using Prism
version 8 (GraphPad, San Diego, CA). 95% confidence
intervals (CIs) for the difference of the means between groups
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are also provided when a t test was performed. p <0.05 (2
sided) was considered significant.
Results
Clinical features
A-II-3 was a 2.5-year-old male of Filipino nonconsanguineous
descent (figure 1A) who presented with left hemiparesis.
Brain MRI revealed an acute right middle cerebral artery
(MCA) territory infarct (figure 1, D and E) with an estab-
lished left-sided infarct in the periventricular white matter.
Brain MRA and catheter angiography revealed bilateral oc-
clusive arteriopathy involving the internal carotid artery
(ICA), with basal collaterals (figure 1, F–H). Of note, visceral
digital subtraction angiography and echocardiography were
normal. There was no acute phase response (ESR 5 mm/h;
reference range <10 mm/h; CRP 5 mg/L; reference range
<20 mg/L); antineutrophil cytoplasmic antibody and anti-
nuclear antibody testing was negative. Other metabolic and
infectious disease investigations, including CSF analyses, were
negative. As he was noted to have 2 café-au-lait spots, genetic
screening of NF1 gene mutations was undertaken through
routine clinical laboratory testing, which excluded any path-
ogenic variants. In addition, array comparative genomic hy-
bridization did not detect any copy number variants. He was
also identified to have factor XII deficiency (factor XII levels
32 IU/L; normal range 50–150 IU/L), but did not experience
any bleeding episodes, and had no evidence of intracerebral
hemorrhage on radiologic imaging. He was started on aspirin
(5 mg/kg/d), and at age 4 years, he underwent bilateral pial
synangiosis. He has not had any further neurologic events.
B-III-2 was a 4-month-old female of Caucasian non-
consanguineous descent (figures 1B and 2, A–F) who pre-
sented with an encephalopathy and left-sided focal seizures in
the context of acute dehydration. She had a history of pul-
monary valve stenosis diagnosed at birth, which had been
surgically corrected. Brain MRI revealed acute swelling and
signal change with restricted diffusion of the whole right
hemisphere, but sparing the basal ganglia. Subsequent brain
MRA and catheter angiography of the cerebral circulation
showed an occlusive arteriopathy of the terminal ICAs, the
MCA, and the anterior cerebral arteries. Computerized brain
CT showed no intracerebral calcification. There were no
systemic symptoms. There was no acute phase response (ESR
7 mm/h; reference range <10 mm/h and CRP 6 mg/L; ref-
erence range <20 mg/L); antineutrophil cytoplasmic anti-
body and antinuclear antibody testing was negative. Visceral
angiography was normal. Extensive screening for infectious,
metabolic, and other rheumatologic causes was negative.
She was started on aspirin (5 mg/kg/d). She remained
stable with no stroke recurrence, but developed progressive
white matter disease in the left hemisphere over time. In-
triguingly, her sister (B-III-1) also had a history of learning
difficulties and was identified to have a similar pattern of
arteriopathy on brain vascular imaging (figure 2, D–F), Her
mother (B-II-2) had a history of dyspraxia and sensorineural
hearing loss, but no clinical history suggestive of stroke.
Brain MRI showed signal abnormality in the left mid-pons
of uncertain significance, no evidence of acute ischemic
stroke, and vascular imaging revealed the same pattern of
arteriopathy (figure 2, G–I). Both affected siblings have
undergone revascularization procedures: B-III-1 had mul-
tiple burr hole surgery, and B-III-2 had a left-sided
encephaloduroarteriosynangiosis.
C-II-6 (figure 2, K–M), of Caucasian, nonconsanguineous
descent, was born with an uncomplicated delivery, but was
noted to be floppy in the first year of life, with gross and fine
motor delay. During pediatric review at age 7 months for
treatment of pneumonia, he was found to have hep-
atosplenomegaly. Despite numerous investigations at that
stage, no clear cause was identified for his delayed de-
velopment and hepatosplenomegaly. Over the years, he was
noted to have down-slanting palpebral fissures, full lips, and
progressive lymphedema. At age 29 years, he presented
acutely with left-sided focal seizures and left hemiparesis and
was subsequently found to have an acute right-sided intra-
parenchymal hemorrhage, with ventricular extension on brain
MRI, and occlusive arteriopathy of the terminal ICAs with
collaterals on angiography. He died despite neurosurgical
intervention. Array comparative genomic hybridization did
not find any copy number variants, and thus, further genetic
testing was requested.
Genetic sequencing
Whole-exome sequencing (WES) in A-II-3 revealed a novel
variant, NM_005188:c.1110_1112del (p.L370_
Y371delinsF), in CBL, a non-frameshift deletion of 3
nucleotides (ATA) resulting in the loss of 2 residues (a leu-
cine and a tyrosine) and to the insertion of phenylalanine in
the linker region of Cbl. The linker region contains 2 con-
served tyrosine residues, Tyr-368 and Tyr-371, whose phos-
phorylation activates and positively regulates E3 ligase activity
of Cbl. This variant was not detected in his unaffected siblings
and parents.
WES of B-III-1, B-II-2, and B-III-2 revealed an intronic mu-
tation in CBL: NM_005188:c.1228-2A>G in CBL present in
the affected siblings and their mother and absent in the father
(B-II-1) and maternal grandparents (B-I-1 and B-I-2). This
variant was predicted to affect splicing and occurs upstream of
exon 9, which encodes part of the RING finger domain of Cbl.
C-II-6 had a rare heterozygous missense mutation in CBL,
identified posthumously: NM_005188:c.1100C>A (p.Q367P).
This residue is located in the linker region of Cbl.
All variants detected using WES were confirmed with Sanger
sequencing. In silico predictive tools (SIFT, MutationTaster,
and PolyPhen-2) predicted that all these variants were likely
to be damaging. Screening of the WES data sets for any other
known genetic variants associated with cerebral arteriopathy
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did not identify any other pertinent Class 4 or Class 5 variants
or any other variants in candidate genes of interest.
Cbl-mediated ubiquitination activity in PBMCs
from patients with heterozygous CBL variants
To determine whether mutant Cbl protein retains E3 ligase
activity, we assessed ubiquitination of known Cbl substrate in
patient-derived PBMCs. Cbl is ubiquitously expressed and
negatively regulates various receptor protein tyrosine kinase
signaling pathways via receptor degradation, thus acting as an
adaptor protein in tyrosine phosphorylation-dependent sig-
naling.13 In PBMCs, EGFR is one such receptor protein ty-
rosine kinase that soon after activation undergoes Cbl-
dependent polyubiquitination and proteosomal degrada-
tion.14 On polyubiquitination of targets, Cbl then promotes
its own polyubiquitination and subsequent autode-
gradation.14 We observed that Cbl protein from WT/WT
PBMCs promoted robust polyubiquitination of EGFR,
whereas Cbl fromWT/c.1110_1112del PBMC (from B-III-1
and B-III-2) showed diminished capacity to polyubiquitinate
EGFR (figure 1I). Similar results were observed for A-II-3.
These results suggested that the heterozygous CBLmutations
we detected in our patients resulted in loss of Cbl-mediated
ubiquitination activity.
Cbl-regulated cell surface receptor
degradation and MAPK signaling in PBMCs
from patients with heterozygous CBL variants
Given the differences we observed in the ubiquitination ca-
pacity of PBMCs from our patients, we next explored whether
Figure 2 Cerebral and MRI angiography findings in patients with heterozygous CBL mutations and cerebral arteriopathy
(A–C) Catheter angiogram (CA) for B-III-2 demonstrated a small and poorly filling right internal carotid artery (RICA), stenosed at the skull base (red arrow) and
occluded at cavernous segment. The hemisphere was filled via moyamoya collaterals (red arrow) and a fetal right posterior cerebral artery (PCA). The left
terminal internal carotid was severely stenosed and filled only a stenosed left middle cerebral artery (MCA) and multiple moyamoya collaterals. The right
vertebral artery (VA) and basilar artery were small and did not fill the PCAs. (D–F) CA images for B-III-1 are shown. The RICA was occluded its cavernous
segment with filling of some vessels viamultiplemoyamoya collaterals. The left ICA was occluded at the cavernous segment with severe stenosis of proximal
anterior cerebral artery (ACA) andMCA andmultiple moyamoya collaterals. The left VA was occluded, and the right VA is stenosed shortly before forming the
basilar artery, which is small and which was occluded at it terminus with no filling of the PCAs. Multiple pial collaterals were visible. (G–I) (blue arrows) MRA
images for B-II-2 revealed bilateral occlusion of the terminal ICAs (red arrows) with filling of distal vessels via moyamoya collaterals. The posterior circulation
appeared patent but attenuated with pial collateral formation. (J–L) CA for C-II-6 revealed bilateral occlusion of the terminal ICAs with no distal filling via
normal intracranial vasculature but some filling of the hemispheres from external carotid–internal carotid and skull base collaterals. The P1 segment of the
right PCA was occluded (red arrow), but multiple pial collaterals were seen filling the hemispheres (blue arrow). CBL = casitas B-lineage lymphoma.
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there was reduced cellular degradation of the Cbl-regulated
cell surface receptor EGFR and the potential impact of that on
downstream EGFR-mediated MAPK signaling. After 120
minutes of treatment with epidermal growth factor (EGF;
a growth factor that stimulates the EGFR), we observed that
relative EGFR expression and MAPK phosphorylation in
patient-derived PBMCs were increased compared with
healthy control cells (p = 0.03 and p = 0.008; figure 1, J and
K). These results suggested aberrant growth factor receptor
degradation and signaling associated with mutant Cbl in
PBMCs from patients with heterozygous CBL mutations and
cerebral arteriopathy.
siRNA-mediated silencing of CBL in endothelial
cells: effects on VEGFR-2–induced tyrosine
kinase signaling and angiogenesis
We next explored whether defective degradation of Cbl-
regulated cell surface receptors enhances tyrosine kinase sig-
naling in endothelial cells, thus promoting angiogenesis and
contributing to the moyamoya capillary pattern we observed
in our patients. It is well established that endothelial cell ac-
tivation of the signaling effector PLC-γ1 through VEGF re-
ceptor 2 (VEGFR-2) is in part responsible for angiogenesis in
vivo.15,16 Cbl E3 ubiquitin ligase constitutively associates with
PLC-γ1 via its C-terminal domain and conditionally interacts
with VEGFR-2 via the N-terminal/TKB domain, acting as
a negative regulator of the signal transduction pathway that
controls angiogenesis.15,16 We therefore examined whether
there was attenuation of VEGFR-2 induced tyrosine kinase
signaling in siRNA CBL-transfected HUVECs compared with
scrambled control endothelial cells. Silencing of CBL by
siRNA in HUVECs resulted in significant upregulation of the
relative expression for the VEGFR-2–induced signaling ef-
fector PLC-γ1 compared with control cells, p = 0.04 (figure
3A) and also enhanced HUVEC capillary network formation
in matrigel (difference between means 21.29 ± 6.427, 95% CI
5.3–27, p = 0.02; figure 3, B and C). These results indicated
that silencing CBL enhances VEGFR-2–induced signal
transduction in endothelial cells, promoting angiogenesis.
PDFGR-induced tyrosine kinase signaling and
SMCmyofibroblast proliferation andmigration
in patients with heterozygous CBL variants
The vascular pathology observed in several other genetic ce-
rebral arteriopathies relates to increased proliferation and
migration of SMCs and myofibroblasts to the medial layer of
the cerebral arterial wall that subsequently causes arterial
occlusion.17 We thus also sought to determine whether ab-
errant degradation of Cbl-regulated surface receptors associ-
ated with mutant CBL enhanced cellular signaling pathways
and promoted fibroblast and myofibroblast proliferation and
migration.
Dermal fibroblasts directly explanted from patients (A-II-2,
B-III-1, B-III-2, and B-II-2) were exposed to transforming
growth factor 1 and trans-differentiated into SMCs. These
cells exhibited enhanced migration (difference between
means 6.2 ± 1.595, 95% CI 2.774–9.776, p = 0.02; figure 3, D
and E), increased proliferation (difference between means
3.14 ± 1.087, 95% CI 0.1228–6.157, p = 0.045; figure 3F), and
upregulation of MAPK expression compared with control
cells (difference between means 0.65 ± 0.441, 95% CI −0.573
to 1.875, p = 0.04; figure 3G). siRNA silencing of CBL had
a similar effect on the migratory capacity of HBVAF (differ-
ence between means 3.283 ± 1.544, 95% CI 0.03–6.5, p =
0.04), proliferation (difference between means 1.907 ± 0.07,
95% CI 1.691–2.123, p = 0.0001), and for phosphorylated
MAPK expression (difference between means 0.884 ± 0.4778,
95% CI −0.4425 to 2.21, p = 0.01). Therefore, these results
suggested that mutant Cbl enhances PDFGR-induced tyro-
sine kinase signaling and promotes SMC proliferation and
migration in patients with heterozygous variants in CBL and
cerebral arteriopathy.
Inhibition of the RAF-RAS-MAPK pathway:
effects on the migratory and proliferative
capacity of fibroblasts derived from patients
with heterozygous CBL variants
We next examined whether targeting the RAF-RAS-MAPK
pathway with sorafenib, a multikinase inhibitor with activity
against RAF kinase, suppresses the enhanced proliferative and
migratory capacity of HDFCs derived from patients with
heterozygous CBL variants. Resting and PDGF-treated
patient-derived HDFCs treated with 5 μM of sorafenib
exhibited suppression of migratory and proliferative capacity
to levels seen in controls cells (figure 4, A and B).
Arterial histology associated with
heterozygous CBL variants
Analysis of the arterial tissue from dural biopsy obtained
post–IC-EC procedure for A-II-3 showed positive pERK
staining in endothelial cells (figure 4C).
Discussion
We identified heterozygous mutations in CBL in several
patients presenting with cerebrovascular disease and provide
an insight into how mutant Cbl could mechanistically cause
this arteriopathy (figure 5). We show that impaired Cbl-
mediated degradation of cell surface receptors and dysregu-
lated intracellular signaling through the RAS-MAPK pathway
may contribute to the pathogenesis of CBL-mediated arte-
riopathy. Mutated CBL failed to control the angiogenic signal
relay of VEGFR-2 and led to subsequent prolonged PLC-γ1
activation in endothelial cells, thus enhancing vascular an-
giogenesis and capillary network formation, and thus possibly
contributing to the basal collateral vessel formation we ob-
served. Mutant CBL also promoted myofibroblast migration
and proliferation via the PDGF receptor pathway, which
could contribute to the vascular occlusive disorder observed
in patients with heterozygous CBL mutations. These effects
were abrogated in vitro following treatment with a RAS
pathway inhibitor.
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Genetic factors have long been suspected in cerebral arte-
riopathy such as moyamoya arteriopathy, based on increased
incidence in certain ethnicities (especially East Asians) and
a familial case prevalence of 10%.18 For instance, variants of
RNF213 account for the genetic susceptibility of Asian
patients, with approximately 80% with moyamoya harboring
the heterozygous p.R4810K founder variant.19 RNF213 has
been shown in vivo and in vitro to play a significant role in
controlling angiogenesis through regulating the expression of
matrix metalloproteinases in endothelial cells.20 We now ex-
pand the spectrum of genetic arteriopathies to include CBL-
mediated arteriopathy. We observed that mutated Cbl sig-
nificantly inhibited E3 ubiquitin ligase activity and overall led
to loss of negative control over the expression of several re-
ceptor tyrosine kinases, including EGFR, VEGFR-2, and
PDGR, thus enhancing downstream signaling pathways such
as the RAS-MAPK pathway. Occlusive vascular disease could
arise secondary to this increased cellular proliferation caused
by aberrant receptor tyrosine kinase signaling. In line with
previous studies, we also show that mutant CBL function
abrogates downregulation of active PLC-γ1, subsequently
increasing angiogenesis.15,16 Ubiquitination of PLC-γ1 by
Figure 3 Enhanced angiogenesis in siRNA CBL-transfected endothelial cells and enhanced proliferation, migration, and
PDFGR-induced tyrosine kinase signaling in smooth muscle cells (SMCs) from patients with heterozygous CBL
mutation
(A) Human umbilical endothelial vein cells (HUVECs) were transfected with siRNA targeting CBL or a scrambled siRNA control and then stimulated with 20 ng/
mL VEGF for the indicated periods of time before staining to explore expression of phosphorylated PLC-γ1. Silencing of CBL resulted in significant upregu-
lation of relative phosphorylated-PLC-γ1 expression in siRNA CBL transfected cells compared with control scrambled transfected HUVECs, p = 0.04. (B)
Representative images of HUVEC capillary network formation on matrigel for resting endothelial cells, scrambled control siRNA, and CBL siRNA-transfected
endothelial cells. Five independent fields were assessed for each well and the mean numbers of tube branches determined. (C) There was enhanced HUVEC
capillary network formation in a matrigel assay in siRNA CBL-transfected cells compared with scrambled control cells, p = 0.02. (D and E) Human dermal
fibroblast cells (HDFCs) from patients with heterozygous CBLmutations were treated with 5 ng/mL transforming growth factor 1 for 14 days to induce trans-
differentiation into SMCs. A standard scratch assay was then performed on culturedmonolayer of SMCs derived fromHDFCs of healthy controls and patients
with CBLmutations. There was an increase in migration of SMC patients with heterozygous CBL mutations compared with control WT/WT cells, p = 0.02. (F)
Patient-derived SMC-like cells/myofibroblasts also exhibited enhanced proliferation when compared with control cells, p = 0.045. (G) SMC-like cells/myofi-
broblasts were stimulated with 20 ng/mL PDGF for the indicated periods of time before staining to explore changes in phosphorylated MAPK expression.
There was enhanced phosphorylation of MAPK at 60 minutes induced by PDGF receptor in patient-derived SMCs compared with control cells, p = 0.04. Data
were expressed as fold change relative to mean baseline expression for control and plotted as mean of triplicate samples ± SEM. p < 0.05 calculated by
analysis of variance and unpaired t tests were considered significant. CBL = casitas B-lineage lymphoma; MAPK = mitogen-activated protein kinase; PDGF =
platelet-derived growth factor.
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CBL serves as an inhibitory mechanism to VEGFR-2–induced
angiogenesis.15,21 This loss of negative control of VEGFR-
2–induced angiogenesis could be relevant to the development
of the basal collateral network, which characterizes the ra-
diologic moyamoya arteriopathy phenotype. Our findings are
also in keeping with previous animal model studies showing
that mutant CBL enhances angiogenesis in zebrafish.15
Analysis of the arterial tissue obtained from A-II-3 showed
pERK-positive staining in endothelial cells, providing direct
evidence of abnormal signaling of this pathway in affected ce-
rebral vasculature from a patient. Additional evidence for the
specificity of our findings comes from the inhibition experi-
ments with sorafenib that specifically targets the RAF-RAS-
MAPK signaling pathway. Treatment with this therapeutic
agent in vitro suppressed the enhanced migratory and pro-
liferative capacity of fibroblasts obtained from patients with
heterozygous CBL variants to levels seen in cells obtained from
healthy controls. It remains to be established whether treat-
ments targeting this pathway can prevent stroke recurrence in
patients with arteriopathy associated with mutant Cbl.
Of interest, previous studies have suggested that germline
mutations of CBL define predisposition to juvenile myelo-
monocytic leukemia.6,7 None of our patients developed a he-
matologic malignancy to date. It may be the case that
heterozygous CBL mutations lead to dysregulation in cell
proliferation via the RAS-MAPK pathway, but do not cause
malignancy unless reduced to homozygosity in target tissue.
This could indicate that a homozygous state or a “two-hit”
process is necessary for oncogenicity.
We suggest that clinicians should consider CBL screening in
patients with moyamoya-like and other systemic arterio-
pathies, even in the absence of obvious developmental ab-
normalities or malignant hematologic manifestations
suggestive of a typical RASopathy. The radiologic appear-
ances we observed in association with heterozygous CBL
mutation were of an occlusive arteriopathy with extensive
basal collaterals, unlike the lack of collateral formation seen
for instance in ACTA2-related arteriopathies.17 More atypical
and heterogeneous imaging findings could ultimately also be
a feature of arteriopathy caused byCBLmutation, however, an
Figure 4 Inhibition of the RAF-RAS-MAPK pathway supresses themigratory and proliferative capacity of fibroblasts derived
from patients with heterozygous CBL variants
(A and B) Resting and PDGF-treated patient-derived human dermal fibroblast cells (HDFCs) explanted from B-II-2, B-III-1, and B-III-2 were treated with 5 μMof
sorafenib, a protein kinase inhibitor that targets the RAF-RAS-MAPK pathway. Treatment with sorafenib suppressed the migratory and proliferative capacity
of HDFCs derived from patients to levels seen in controls cells. (C) Immunohistochemistry for pERK on dura taken during surgery on patient A-II-3 showed
strong endothelial expression (arrow) in dural blood vessels. Scare bar is 50μm.CBL = casitas B-lineage lymphoma;MAPK =mitogen-activated protein kinase;
PDGF = platelet-derived growth factor.
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issue that will become clearer as more patients are described.
Thus, the contribution of CBL mutations to other occlusive
cerebral arteriopathies and arterial ischemic stroke remains to
be established in future prospective studies of genetic
screening in larger cohorts of unselected cases.
Although all affected patients had cerebral arteriopathy, we
acknowledge the heterogeneity of presentation in the cohort
of patients described herein. It is possible that additional
mechanisms promoting fibroblast proliferation andmigration,
angiogenesis, and collateral formation are involved in CBL-
mediated arteriopathy. The specificity of our proposed
mechanism for CBL-mediated cerebral arteriopathy needs to
be established in larger cohorts, including repeating similar
biological assays in cases with a similar radiologic cerebral
arteriopathy phenotype but with no CBL variants identified.
Genotype-phenotype correlations were not possible in this
cohort, but may become apparent as more cases are described.
None of the patients had evidence of a systemic arteriopathy
on initial screening, but vascular surveillance is ongoing in
light of previous reports suggesting that several genetic arte-
riopathies causing stroke are not just confined in the CNS and
may be more widespread than previously considered.17,22
In summary, we describe monoallelic variants in CBL in patients
from 3 unrelated kindreds as the likely cause of cerebral arterio-
pathy. We provide a possible mechanism for the observed arte-
riopathy through impaired CBL-mediated degradation of cell
surface receptors and dysregulated intracellular RAS signaling.
Future exploration of this pathway could facilitate identification of
novel or repurposed druggable targets for cerebral arteriopathy.
Acknowledgment
The authors thank the patients and families who took part in
this study.
Study funding
Y. Hong was supported for this work by Versus Arthritis (grant
21791) and Rosetrees Trust (grant A1700). D. Eleftheriou was
supported by Versus Arthritis (grants 20164 and 21593). A.
Keylock was supported by a BHF PhD studentship. B. Jensen is
supported by a GOSH Children’s Charity grant (CP_
RSRCH_003). P.A. Brogan and D. Eleftheriou also acknowl-
edge support from Great Ormond Street Hospital Children’s
Charity. All research at Great Ormond Street Hospital NHS
Foundation Trust and UCL Great Ormond Street Institute of
Child Health is made possible by the NIHR Great Ormond
Street Hospital Biomedical Research Centre. The views
expressed are those of the author(s) and not necessarily those
of the NHS, the NIHR, or the Department of Health.
Disclosure
Y. Hong, A. Keylock, B. Jensen, T.S. Jacques, E. Omoyinmi, D.
Saunders, O. Ogunbiyi, A.A. Mallick, M. Tooley, R. Newbury-
Ecob, J. Rankin, H.J. Williams, and V. Ganesan have no dis-
closures. P.A. Brogan has received consultancy fees and re-
search grants from SOBI, Roche, UCB, Novartis, and
Novimmune. D. Eleftheriou has received consultancy fees and
Figure 5 Schematic representation of possible disease mechanisms in arteriopathy associated with mutant CBL
Loss of Cbl-mediated ubiquitination activity in mutant CBL endothelial and smooth muscle cells results in reduced CBL-regulated cell surface receptor
degradation and enhanced cellular tyrosine kinase signaling promoting angiogenesis, collateral vessel formation, smooth muscle cell proliferation and
migration, and vascular stenosis. CBL = casitas B-lineage lymphoma; MAPK =mitogen-activated protein kinase; P = phosphorylated; PDGF = platelet-derived
growth factor; TK = tyrosine kinase; Ub = ubiquitination; VEGF = vascular endothelial growth factor.
10 Neurology: Genetics | Volume 6, Number 4 | August 2020 Neurology.org/NG
research grants from SOBI, Roche, Pfizer, and Lilly. Go to
Neurology.org/NG for full disclosures.
Publication history
Received by Neurology: Genetics March 6, 2020. Accepted in final form
April 28, 2020.
References
1. Available at: genecards.org/cgi-bin/carddisp.pl?gene=CBL. Accessed January 2020.
2. Masson K, Heiss E, Band H, Rönnstrand L. Direct binding of Cbl to Tyr568 and
Tyr936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiq-
uitination, internalization and degradation. Biochem J 2001;399:59–67.
3. Katz M, Amit I, Yarden Y. Regulation of MAPKs by growth factors and receptor
tyrosine kinases. Biochim Biophys Acta 2007;1773:1161–1176.
4. Perez B, Mechinaud F, Galambrun C, et al. Germline mutations of the CBL gene
define a new genetic syndrome with predisposition to juvenile myelomonocytic
leukaemia. J Med Genet 2010;47:686–691.
5. Guey S, Grangeon L, Brunelle F, et al. De novo mutations in CBL causing early-onset
paediatric moyamoya angiopathy. J Med Genet 2017;54:550–557.
6. Hyakuna N,MuramatsuH,Higa T, Chinen Y,Wang X, Kojima S. Germlinemutation of
CBL is associated with moyamoya disease in a child with juvenile myelomonocytic
leukemia and Noonan syndrome-like disorder. Pediatr Blood Cancer 2015;62:542–544.
7. Niemeyer CM, Kang MW, Shin DH, et al. Germline CBL mutations cause de-
velopmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat
Genet 2010;42:794–800.
8. Eleftheriou D, Ganesan V, Hong Y, Klein NJ, Brogan PA. Endothelial injury in
childhood stroke with cerebral arteriopathy: a cross-sectional study. Neurology 2012;
79:2089–2096.
9. Wintermark M, Hills NK, DeVeber GA, et al. Clinical and imaging characteristics of
arteriopathy subtypes in children with arterial ischemic stroke: results of the VIPS
study. AJNR Am J Neuroradiol 2017;38:2172–2179.
10. Hong Y, Eleftheriou D, Hussain AA, et al. Anti-neutrophil cytoplasmic antibodies
stimulate release of neutrophil microparticles. J Am Soc Nephrol 2012;23:49–62.
11. Milewicz DM, Trybus KM, Guo DC, et al. Altered smooth muscle cell force gener-
ation as a driver of thoracic aortic aneurysms and dissections. Arterioscler Thromb
Vasc Biol 2017;37:26–34.
12. Wallis YPS, McAnulty C, Bodmer D, et al. Practice Guidelines for the Evaluation of
Pathogenicity and the Reporting of Sequence Variants in Clinical Molecular Genetics.
2013. Available at: acgs.uk.com/media/10791/evaluation_and_reporting_of_se-
quence_variants_bpgs_june_2013_-_finalpdf.pdf. Accessed January 2020.
13. Mohapatra B, Ahmad G, Nadeau S, et al. Protein tyrosine kinase regulation by
ubiquitination: critical roles of Cbl-family ubiquitin ligases. Biochim Biophys Acta
2013;1833:122–139.
14. Visser Smit GD, Place TL, Cole SL, et al. Cbl controls EGFR fate by regulating early
endosome fusion. Sci Signal 2009;2:ra86.
15. Shivanna S, Harrold I, Shashar M, et al. The c-Cbl ubiquitin ligase regulates nuclear
beta-catenin and angiogenesis by its tyrosine phosphorylation mediated through the
Wnt signaling pathway. J Biol Chem 2015;290:12537–12546.
16. Singh AJ, Meyer RD, Navruzbekov G, et al. A critical role for the E3-ligase activity of
c-Cbl in VEGFR-2-mediated PLCgamma1 activation and angiogenesis. Proc Natl
Acad Sci USA 2007;104:5413–5418.
17. Guo DC, Papke CL, Tran-Fadulu V, et al. Mutations in smooth muscle alpha-actin
(ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with
thoracic aortic disease. Am J Hum Genet 2009;84:617–627.
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